ArticleJournal of pharmaceutical policy and practice2025

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial.

Yiling Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.